在2型糖尿病中检测高通量安全信号的-葡萄糖共传输体-2抑制剂
Hao Dai1, Yao An Lee2, Jiang Bian1,3,4,5
1Department of Biostatistics & Health Data Science, Indiana University, Indianapolis, IN, USA.
medRxiv : the preprint server for health sciences
|December 8, 2025
概括
这项研究使用了现实世界的数据,以在2型糖尿病患者中发现-葡萄糖共运输体-2抑制剂 (SGLT2i) 的安全信号. 它证实了已知的风险,并确定了潜在的新不良事件,改善了药物安全监测.
科学领域:
- 药物监督 药物监督 药物监督
- 糖尿病研究中的现实世界的证据.
- 计算流行病学计算流行病学
背景情况:
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 广泛用于2型糖尿病 (T2D).
- 营销后监测对于识别罕见或长期不良事件至关重要.
- 需要高通量方法来有效地分析大型电子健康记录 (EHR) 数据集.
研究的目的:
- 在T2D患者中系统地识别与SGLT2i相关的潜在安全信号.
- 将高通量目标试验仿真管道应用于现实世界EHR数据.
- 通过检测已知的不良事件来验证方法.
主要方法:
- 使用EHR数据进行回顾性新用户队列设计 (OneFlorida+数据信任,2012-2023).
- 比较SGLT2i启动剂与其他二线降血糖药物 (GLDs) 启动剂.
- 半贝叶斯收缩方法用于调整多次测试和罕见结果的危险比率 (HR) 和p值.
主要成果:
- 确定了统计学上显著的安全信号,包括已知的事件,如 vulvovaginal candidasis (HR=1.64).
- 确认已知的不良事件,验证了研究的方法.
- 检测出病毒结膜炎和黑色细胞瘤等疾病的潜在新安全信号.
结论:
- 高通量选有效地确定了SGLT2i.i.的已知和潜在的新安全信号.
- 半贝叶斯缩为大型医疗保健数据库中的营销后监测提供了一个强大的框架.
- 这种方法增强了使用现实数据系统识别药物安全信号.
相关概念视频
Secondary Active Transport
136.5K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.5K
Secondary Active Transport
9.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.2K
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Glucose Absorption Into the Small Intestine
34.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.7K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565


